PDCD1 and melanoma: Nonetheless, longitudinal research conducted on melanoma patients treated with ICB showed, through repeated biopsies, that variations in the TME composition between responders and non-responders were more pronounced following two or three administrations of anti-PD-1 than at baseline [127,128].